HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%
Phase 1Terminated 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Genital Herpes
Conditions
Genital Herpes
Trial Timeline
Feb 18, 2020 โ May 19, 2021
NCT ID
NCT04222985About HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9% is a phase 1 stage product being developed by Merck for Genital Herpes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04222985. Target conditions include Genital Herpes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04222985 | Phase 1 | Terminated |
Competing Products
20 competing products in Genital Herpes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| ASP2151 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP2151 + valacyclovir + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tildrakizumab 100 mg + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Gemcitabine + Paclitaxel + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Daratumumab | Johnson & Johnson | Phase 2 | 52 |
| Risankizumab + Placebo for Risankizumab | AbbVie | Approved | 85 |